Search research articles
Contact Us
Filters
Showing results (331-340 of 349) with videos related to
Page
of 35
Sort By:
Journal of Medicinal Chemistry
|
July 21, 1998
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements
S E Webber, K Okano, T L Little, et al.
American Journal of Medical Genetics. Part A
|
November 26, 2009
Genome-wide linkage scan of nonsyndromic orofacial clefting in 91 families of central European origin
Elisabeth Mangold, Heiko Reutter, Stefanie Birnbaum, et al.
Nature Medicine
|
January 16, 2019
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Yichen Xu, Mauro Poggio, Hyun Yong Jin, et al.
Journal of Medicinal Chemistry
|
May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase
Justin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
European Journal of Oral Sciences
|
February 4, 2010
IRF6 gene variants in Central European patients with non-syndromic cleft lip with or without cleft palate
Stefanie Birnbaum, Kerstin U Ludwig, Heiko Reutter, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
October 20, 2012
Resequencing of VAX1 in patients with nonsyndromic cleft lip with or without cleft palate
Entessar Nasser, Elisabeth Mangold, Daniela C Tradowsky, et al.
Journal of Medicinal Chemistry
|
May 3, 2002
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease
Theodore O Johnson, Ye Hua, Hiep T Luu, et al.
Journal of Medicinal Chemistry
|
December 16, 1997
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease
S W Kaldor, V J Kalish, J F Davies, et al.
Molecular Cancer Therapeutics
|
October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
Peggy A Thompson, Boreth Eam, Nathan P Young, et al.
BMC Cancer
|
November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center
Marie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 349) with videos related to
Sort By:
Page
of 35
Journal of Medicinal Chemistry
|
July 21, 1998
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements
S E Webber, K Okano, T L Little, et al.
American Journal of Medical Genetics. Part A
|
November 26, 2009
Genome-wide linkage scan of nonsyndromic orofacial clefting in 91 families of central European origin
Elisabeth Mangold, Heiko Reutter, Stefanie Birnbaum, et al.
Nature Medicine
|
January 16, 2019
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Yichen Xu, Mauro Poggio, Hyun Yong Jin, et al.
Journal of Medicinal Chemistry
|
May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase
Justin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
European Journal of Oral Sciences
|
February 4, 2010
IRF6 gene variants in Central European patients with non-syndromic cleft lip with or without cleft palate
Stefanie Birnbaum, Kerstin U Ludwig, Heiko Reutter, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
October 20, 2012
Resequencing of VAX1 in patients with nonsyndromic cleft lip with or without cleft palate
Entessar Nasser, Elisabeth Mangold, Daniela C Tradowsky, et al.
Journal of Medicinal Chemistry
|
May 3, 2002
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease
Theodore O Johnson, Ye Hua, Hiep T Luu, et al.
Journal of Medicinal Chemistry
|
December 16, 1997
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease
S W Kaldor, V J Kalish, J F Davies, et al.
Molecular Cancer Therapeutics
|
October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
Peggy A Thompson, Boreth Eam, Nathan P Young, et al.
BMC Cancer
|
November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center
Marie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.
Page
of 35